secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2021-10-05T23:59:59+00:00
Accession:  0001104659-21-122758
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco to carve out microbiome R&D platform; appoints new innovation chief
--------------------------------------------------------------------------

- Ellen de Brabander, Ph.D., named EVP of Innovation and Regulatory Affairs, effective Oct 18, 2021.
- Aaron Schacht will lead the carve-out of Elanco's microbiome R&D platform into an independent biopharma company.
- Carve-out expected by Q1 2022; Elanco may retain minority stake; J.P. Morgan advising.
- Elanco reaffirms 2025 innovation revenue target of $600–700M, supported by KindredBio acquisition and pipeline.
- Pet health portfolio increased as a percentage of pipeline; focus on high-value late-stage candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000110465921122758/0001104659-21-122758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000110465921122758/tm2129160d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-122758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer